{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:54:20Z","timestamp":1791345260072,"version":"4.3.1"},"reference-count":167,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.pharmthera.2023.108460","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T20:59:05Z","timestamp":1685048345000},"page":"108460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Is there a role for specialized pro-resolving mediators in pulmonary fibrosis?"],"prefix":"10.1016","volume":"247","author":[{"given":"Thomas H.","family":"Thatcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.T.","family":"Freeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Par Aung","family":"Myo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia J.","family":"Sime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2023.108460_bb0005","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1111\/bph.13203","article-title":"The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFbeta-induced pulmonary fibrosis","volume":"172","author":"Abdalla","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01147","article-title":"Eicosapentaenoic acid enhances the effects of mesenchymal stromal cell therapy in experimental allergic asthma","author":"Abreu","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0015","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1096\/fj.14-265363","article-title":"Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice","volume":"29","author":"Akagi","year":"2015","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0020","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3389\/fphar.2018.01327","article-title":"Opposing effects on vascular smooth muscle cell proliferation and macrophage-induced inflammation reveal a protective role for the proresolving lipid mediator receptor ChemR23 in Intimal hyperplasia","volume":"9","author":"Artiach","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/mi.2016.61","article-title":"Periostin regulates fibrocyte function to promote myofibroblast differentiation and lung fibrosis","volume":"10","author":"Ashley","year":"2017","journal-title":"Mucosal Immunology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2019.105598","article-title":"Small airway fibrosis in COPD","volume":"116","author":"Barnes","year":"2019","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"818-833","key":"10.1016\/j.pharmthera.2023.108460_bb0035","article-title":"Inhibiting eicosanoid degradation exerts antifibrotic effects in a pulmonary fibrosis mouse model and human tissue","volume":"145","author":"Barnthaler","year":"2020","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0040","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/qjmed\/hcu012","article-title":"Vascular remodelling in the pathogenesis of idiopathic pulmonary fibrosis","volume":"107","author":"Barratt","year":"2014","journal-title":"QJM"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nri.2015.4","article-title":"Specialized pro-resolving mediators: endogenous regulators of infection and inflammation","volume":"16","author":"Basil","year":"2016","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0050","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"The Lancet Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0055","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4049\/jimmunol.2001228","article-title":"AT-RvD1 mitigates secondhand smoke-exacerbated pulmonary inflammation and restores secondhand smoke-suppressed antibacterial immunity","volume":"206","author":"Bhat","year":"2021","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0060","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/08977194.2011.595714","article-title":"TGF-beta signaling in fibrosis","volume":"29","author":"Biernacka","year":"2011","journal-title":"Growth Factors"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0065","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1159\/000508540","article-title":"Azathioprine for connective tissue disease-associated interstitial lung disease","volume":"99","author":"Boerner","year":"2020","journal-title":"Respiration"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0070","doi-asserted-by":"crossref","DOI":"10.1590\/1806-3713\/e20190303","article-title":"Familial pulmonary fibrosis: a world without frontiers","volume":"45","author":"Borie","year":"2019","journal-title":"Jornal Brasileiro de Pneumologia"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0075","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.imbio.2012.05.020","article-title":"Differential role of regulatory T cells in early and late stages of pulmonary fibrosis","volume":"218","author":"Boveda-Ruiz","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0080","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3389\/fphar.2020.01290","article-title":"The role of specialized pro-resolving mediators in cystic fibrosis airways disease","volume":"11","author":"Briottet","year":"2020","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0085","doi-asserted-by":"crossref","first-page":"L193","DOI":"10.1152\/ajplung.00058.2013","article-title":"Lipoxin A(4)-mediated KATP potassium channel activation results in cystic fibrosis airway epithelial repair","volume":"305","author":"Buchanan","year":"2013","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0090","doi-asserted-by":"crossref","first-page":"L1146","DOI":"10.1152\/ajplung.00383.2004","article-title":"PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis","volume":"288","author":"Burgess","year":"2005","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0095","first-page":"67","article-title":"Specialized pro-resolving mediators in respiratory diseases","volume":"25","author":"Cagnina","year":"2022","journal-title":"Current Opinion in Clinical Nutrition and Metabolic Care"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0100","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.bbalip.2014.09.002","article-title":"Transcellular biosynthesis of eicosanoid lipid mediators","volume":"1851","author":"Capra","year":"2015","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0105","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1096\/fj.201700082R","article-title":"Biosynthesis of proresolving lipid mediators by vascular cells and tissues","volume":"31","author":"Chatterjee","year":"2017","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0110","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/09031936.00152106","article-title":"Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis","volume":"29","author":"Chaudhary","year":"2007","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0115","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.mam.2017.03.005","article-title":"Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors","volume":"58","author":"Chiang","year":"2017","journal-title":"Molecular Aspects of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0120","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1042\/EBC20200018","article-title":"Specialized pro-resolving mediator network: an update on production and actions","volume":"64","author":"Chiang","year":"2020","journal-title":"Essays in Biochemistry"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0125","doi-asserted-by":"crossref","first-page":"C1141","DOI":"10.1152\/ajpcell.00351.2012","article-title":"Diversity of lipid mediators in human adipose tissue depots","volume":"304","author":"Claria","year":"2013","journal-title":"American Journal of Physiology. Cell Physiology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0130","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/mi.2017.36","article-title":"Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection","volume":"11","author":"Codagnone","year":"2018","journal-title":"Mucosal Immunology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0135","doi-asserted-by":"crossref","first-page":"C39","DOI":"10.1152\/ajpcell.00024.2014","article-title":"Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue","volume":"307","author":"Colas","year":"2014","journal-title":"American Journal of Physiology. Cell Physiology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0140","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1164\/ajrccm.150.4.7921471","article-title":"The epidemiology of interstitial lung diseases","volume":"150","author":"Coultas","year":"1994","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0145","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.4049\/jimmunol.1502331","article-title":"Resolvin D1 dampens pulmonary inflammation and promotes clearance of nontypeable haemophilus influenzae","volume":"196","author":"Croasdell","year":"2016","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0150","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1096\/fj.14-268441","article-title":"Novel proresolving and tissue-regenerative resolvin and protectin sulfido-conjugated pathways","volume":"29","author":"Dalli","year":"2015","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149319","article-title":"Identification and actions of a novel third maresin conjugate in tissue regeneration: MCTR3","volume":"11","author":"Dalli","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0160","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02419-2016","article-title":"Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris","volume":"50","author":"Duchemann","year":"2017","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0165","doi-asserted-by":"crossref","first-page":"3062274","DOI":"10.1155\/2022\/3062274","article-title":"Modulation of arginase-2 mRNA levels by omega-3 PUFAs and aspirin in asthmatic human lung fibroblasts","volume":"2022","author":"Duggirala","year":"2022","journal-title":"Journal of Lipids"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejphar.2015.11.001","article-title":"DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation","volume":"785","author":"Duvall","year":"2016","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135266","article-title":"Normal human lung epithelial cells inhibit transforming growth factor-beta induced myofibroblast differentiation via prostaglandin E2","volume":"10","author":"Epa","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0180","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI36136","article-title":"VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats","volume":"119","author":"Farkas","year":"2009","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0185","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/resp.13753","article-title":"Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF","volume":"25","author":"Farrand","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0190","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1465-9921-13-64","article-title":"A Newfoundland cohort of familial and sporadic idiopathic pulmonary fibrosis patients: clinical and genetic features","volume":"13","author":"Fernandez","year":"2012","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0195","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190103","article-title":"Transforming growth factor-beta in tissue fibrosis","volume":"217","author":"Frangogiannis","year":"2020","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0200","first-page":"12","article-title":"Fish oil nanoemulsion supplementation attenuates bleomycin-induced pulmonary fibrosis BALB\/c mice","author":"Galdino de Souza","year":"2022","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0205","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.rmed.2011.08.022","article-title":"Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis","volume":"105","author":"Garcia-Sancho","year":"2011","journal-title":"Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0210","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.bbalip.2012.07.011","article-title":"Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS\/MS","volume":"1821","author":"Giera","year":"2012","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910714","article-title":"Epoxyeicosatrienoic acids and fibrosis: recent insights for the novel therapeutic strategies","volume":"22","author":"Guan","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.886601","article-title":"Pleiotropic antifibrotic actions of aspirin-triggered resolvin D1 in the lungs","volume":"14","author":"Guilherme","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0225","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1165\/rcmb.2012-0462OC","article-title":"Pulmonary antifibrotic mechanisms aspirin-triggered lipoxin A(4) synthetic analog","volume":"49","author":"Guilherme","year":"2013","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/d0132de3-56ca-4258-9119-bdab0ceb2cff","article-title":"Myofibroblast differentiation and enhanced TGF-B signaling in cystic fibrosis lung disease","volume":"8","author":"Harris","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0235","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/aps.2011.4","article-title":"Characterization of Quin-C1 for its anti-inflammatory property in a mouse model of bleomycin-induced lung injury","volume":"32","author":"He","year":"2011","journal-title":"Acta Pharmacologica Sinica"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0240","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.bbrc.2015.07.076","article-title":"LXA4 actions direct fibroblast function and wound closure","volume":"464","author":"Herrera","year":"2015","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0245","doi-asserted-by":"crossref","first-page":"L1053","DOI":"10.1152\/ajplung.00368.2015","article-title":"Lipoxin A4 prevents tight junction disruption and delays the colonization of cystic fibrosis bronchial epithelial cells by Pseudomonas aeruginosa","volume":"310","author":"Higgins","year":"2016","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0250","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0255","doi-asserted-by":"crossref","first-page":"L776","DOI":"10.1152\/ajplung.00177.2015","article-title":"Resolvin E1 normalizes contractility, Ca2+ sensitivity and smooth muscle cell migration rate in TNF-alpha- and IL-6-pretreated human pulmonary arteries","volume":"309","author":"Hiram","year":"2015","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0260","doi-asserted-by":"crossref","first-page":"H1547","DOI":"10.1152\/ajpheart.00452.2014","article-title":"Resolvin D1 reverses reactivity and Ca2+ sensitivity induced by ET-1, TNF-alpha, and IL-6 in the human pulmonary artery","volume":"307","author":"Hiram","year":"2014","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0265","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/cvr\/cvaa186","article-title":"The inflammation-resolution promoting molecule resolvin-D1 prevents atrial proarrhythmic remodelling in experimental right heart disease","volume":"117","author":"Hiram","year":"2021","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0270","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.2353\/ajpath.2010.091082","article-title":"Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis","volume":"177","author":"Ho","year":"2010","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0275","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.4049\/jimmunol.1400313","article-title":"Resolvin D1 attenuates polyinosinic-polycytidylic acid-induced inflammatory signaling in human airway epithelial cells via TAK1","volume":"193","author":"Hsiao","year":"2014","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064341","article-title":"Dysregulated proinflammatory and fibrogenic phenotype of fibroblasts in cystic fibrosis","volume":"8","author":"Huaux","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0285","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pupt.2017.10.007","article-title":"The leukotriene receptor antagonist pranlukast attenuates airway remodeling by suppressing TGF-beta signaling","volume":"48","author":"Hur","year":"2018","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0290","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.rmed.2013.09.002","article-title":"A cohort study of interstitial lung diseases in central Denmark","volume":"108","author":"Hyldgaard","year":"2014","journal-title":"Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0295","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Idiopathic Pulmonary Fibrosis Clinical Research, N","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0300","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3389\/fimmu.2020.00581","article-title":"Resolvin D1 reduces lung infection and inflammation activating resolution in cystic fibrosis","volume":"11","author":"Isopi","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0305","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.chest.2020.08.016","article-title":"Mortality trends of idiopathic pulmonary fibrosis in the United States From 2004 through 2017","volume":"159","author":"Jeganathan","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0310","first-page":"3083","article-title":"BML-111 suppresses TGF-beta1-induced lung fi broblast activation in vitro and decreases experimental pulmonary fibrosis in vivo","volume":"42","author":"Ji","year":"2018","journal-title":"International Journal of Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0315","doi-asserted-by":"crossref","first-page":"13794","DOI":"10.1096\/fj.201902003R","article-title":"Biosynthetic metabolomes of cysteinyl-containing immunoresolvents","volume":"33","author":"Jouvene","year":"2019","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22042107","article-title":"Formyl peptide receptor 2 alleviates hepatic fibrosis in liver cirrhosis by vascular remodeling","volume":"22","author":"Jun","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0325","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.adro.2018.05.004","article-title":"Interobserver reliability in describing radiographic lung changes after stereotactic body radiation therapy","volume":"3","author":"Kalman","year":"2018","journal-title":"Advances in Radiation Oncology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0330","doi-asserted-by":"crossref","first-page":"L92","DOI":"10.1152\/ajplung.2001.281.1.L92","article-title":"IL-12 attenuates bleomycin-induced pulmonary fibrosis","volume":"281","author":"Keane","year":"2001","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0335","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fphar.2014.00123","article-title":"Fibroblasts in fibrosis: novel roles and mediators","volume":"5","author":"Kendall","year":"2014","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0340","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/01902148909087861","article-title":"Dietary fish oil inhibits bleomycin-induced pulmonary fibrosis in the rat","volume":"15","author":"Kennedy","year":"1989","journal-title":"Experimental Lung Research"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0345","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s41419-020-02846-7","article-title":"LXA(4)-FPR2 signaling regulates radiation-induced pulmonary fibrosis via crosstalk with TGF-beta\/Smad signaling","volume":"11","author":"Kim","year":"2020","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0350","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s12276-021-00618-7","article-title":"The arachidonic acid metabolite 11,12-epoxyeicosatrienoic acid alleviates pulmonary fibrosis","volume":"53","author":"Kim","year":"2021","journal-title":"Experimental & Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0355","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1165\/rcmb.2016-0121TR","article-title":"Immune mechanisms in pulmonary fibrosis","volume":"55","author":"Kolahian","year":"2016","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0360","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1165\/rcmb.2002-0243OC","article-title":"Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation","volume":"29","author":"Kolodsick","year":"2003","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0365","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1164\/rccm.201201-0084OC","article-title":"Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-beta","volume":"186","author":"Kottmann","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0370","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1002\/art.21432","article-title":"Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators","volume":"52","author":"Kowal-Bielecka","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0375","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/annrheumdis-2011-200745","article-title":"The 12\/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis","volume":"71","author":"Kronke","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0380","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.yjmcc.2020.08.013","article-title":"Eicosapentaenoic acid ameliorates pulmonary hypertension via inhibition of tyrosine kinase Fyn","volume":"148","author":"Kurahara","year":"2020","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0385","doi-asserted-by":"crossref","first-page":"L855","DOI":"10.1152\/ajplung.00272.2016","article-title":"Human lung fibroblasts produce proresolving peroxisome proliferator-activated receptor-gamma ligands in a cyclooxygenase-2-dependent manner","volume":"311","author":"Lacy","year":"2016","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0390","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1165\/rcmb.2017-0248OC","article-title":"Activated human lung fibroblasts produce extracellular vesicles with antifibrotic prostaglandins","volume":"60","author":"Lacy","year":"2019","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0395","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.117.032801","article-title":"ERV1\/ChemR23 signaling protects against atherosclerosis by modifying oxidized low-density lipoprotein uptake and phagocytosis in macrophages","volume":"138","author":"Laguna-Fernandez","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0400","article-title":"Overexpression of apolipoprotein A1 in the lung abrogates fibrosis in experimental silicosis","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0405","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1183\/09031936.00125007","article-title":"Inhibition of VEGF blocks TGF-beta1 production through a PI3K\/Akt signalling pathway","volume":"31","author":"Lee","year":"2008","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0410","doi-asserted-by":"crossref","first-page":"496","DOI":"10.4049\/jimmunol.178.1.496","article-title":"Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness","volume":"178","author":"Levy","year":"2007","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0415","doi-asserted-by":"crossref","first-page":"46754","DOI":"10.1038\/srep46754","article-title":"Posttreatment with Protectin DX ameliorates bleomycin-induced pulmonary fibrosis and lung dysfunction in mice","volume":"7","author":"Li","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0420","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1111\/bph.15906","article-title":"Maresin 1 intervention reverses experimental pulmonary arterial hypertension in mice","volume":"179","author":"Li","year":"2022","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0425","doi-asserted-by":"crossref","DOI":"10.3390\/biom11060789","article-title":"The roles of various prostaglandins in fibrosis: A review","volume":"11","author":"Li","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0430","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1096\/fj.201800173R","article-title":"Resolvin E1 attenuates injury-induced vascular neointimal formation by inhibition of inflammatory responses and vascular smooth muscle cell migration","volume":"32","author":"Liu","year":"2018","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0435","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1074\/jbc.RA118.006615","article-title":"Telomerase reverse transcriptase ameliorates lung fibrosis by protecting alveolar epithelial cells against senescence","volume":"294","author":"Liu","year":"2019","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0440","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4939-7113-8_2","article-title":"The bleomycin model of pulmonary fibrosis","volume":"1627","author":"Liu","year":"2017","journal-title":"Methods in Molecular Biology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109660","article-title":"Lipoxin A4 inhibits ovalbumin-induced airway inflammation and airway remodeling in a mouse model of asthma","volume":"349","author":"Liu","year":"2021","journal-title":"Chemico-Biological Interactions"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0450","article-title":"Inhibitory effects of short-chain fatty acids and omega-3 polyunsaturated fatty acids on profibrotic factors in dermal fibroblasts","volume":"19","author":"Maeshige","year":"2019","journal-title":"Eplasty"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0455","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01603-2017","article-title":"Trends in mortality from idiopathic pulmonary fibrosis in the European Union: an observational study of the WHO mortality database from 2001-2013","volume":"51","author":"Marshall","year":"2018","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0460","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.4049\/jimmunol.0802259","article-title":"ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis","volume":"182","author":"Martins","year":"2009","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0465","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1373\/clinchem.2012.190199","article-title":"Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation","volume":"58","author":"Mas","year":"2012","journal-title":"Clinical Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0470","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/molpharm.121.000422","article-title":"Multipathway in vitro pharmacological characterization of specialized proresolving G protein-coupled receptors","volume":"101","author":"Merlin","year":"2022","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0475","first-page":"343","article-title":"Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis","volume":"11","author":"Meyer","year":"2017","journal-title":"Expert Review of Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0480","doi-asserted-by":"crossref","first-page":"L891","DOI":"10.1152\/ajplung.00333.2007","article-title":"PPAR-{gamma} agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis","volume":"294","author":"Milam","year":"2008","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0485","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1084\/jem.20162152","article-title":"Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span","volume":"214","author":"Misharin","year":"2017","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0490","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1096\/fj.12-225615","article-title":"D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury","volume":"27","author":"Miyahara","year":"2013","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0495","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.chest.2016.10.029","article-title":"Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis","volume":"151","author":"Morisset","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174936","article-title":"Aspirin-triggered resolvin D1 attenuates PDGF-induced vascular smooth muscle cell migration via the cyclic adenosine monophosphate\/protein kinase A (cAMP\/PKA) pathway","volume":"12","author":"Mottola","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0505","doi-asserted-by":"crossref","first-page":"L810","DOI":"10.1152\/ajplung.00403.2018","article-title":"Prostaglandin E(2) inhibits profibrotic function of human pulmonary fibroblasts by disrupting Ca(2+) signaling","volume":"316","author":"Mukherjee","year":"2019","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0510","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0092-8674(00)80545-0","article-title":"The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis","volume":"96","author":"Munger","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0515","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2147\/JIR.S304811","article-title":"MCTR1 intervention reverses experimental lung fibrosis in mice","volume":"14","author":"Pan","year":"2021","journal-title":"Journal of Inflammation Research"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0520","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.7150\/thno.47627","article-title":"Multi-omics study of silicosis reveals the potential therapeutic targets PGD(2) and TXA(2)","volume":"11","author":"Pang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107879","article-title":"Resolution of inflammation: An organizing principle in biology and medicine","volume":"227","author":"Panigrahy","year":"2021","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0530","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1021\/acsptsci.9b00075","article-title":"New advances in targeting the resolution of inflammation: implications for specialized pro-resolving mediator GPCR drug discovery","volume":"3","author":"Park","year":"2020","journal-title":"ACS Pharmacology & Translational Science"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0535","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100073R","article-title":"Fish oil replacement prevents, while docosahexaenoic acid-derived protectin DX mitigates end-stage-renal-disease in atherosclerotic diabetic mice","volume":"35","author":"Perazza","year":"2021","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0540","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.prostaglandins.2013.02.001","article-title":"In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor","volume":"104-105","author":"Podolin","year":"2013","journal-title":"Prostaglandins & Other Lipid Mediators"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0545","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.ajpath.2015.12.012","article-title":"The protectin PCTR1 is produced by human M2 macrophages and enhances resolution of infectious inflammation","volume":"186","author":"Ramon","year":"2016","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0550","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202001952R","article-title":"Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages","volume":"35","author":"Recchiuti","year":"2021","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0555","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.4049\/jimmunol.1500936","article-title":"Lipoxin A4 attenuates constitutive and TGF-beta1-dependent profibrotic activity in human lung myofibroblasts","volume":"195","author":"Roach","year":"2015","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0560","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12931-018-0834-8","article-title":"Epithelial mesenchymal transition (EMT): a universal process in lung diseases with implications for cystic fibrosis pathophysiology","volume":"19","author":"Rout-Pitt","year":"2018","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105694","article-title":"Resolvin D1 (RvD1) and maresin 1 (Mar1) contribute to human macrophage control of M. tuberculosis infection while resolving inflammation","volume":"74","author":"Ruiz","year":"2019","journal-title":"International Immunopharmacology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0570","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000073718","article-title":"Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro","volume":"132","author":"Saito","year":"2003","journal-title":"International Archives of Allergy and Immunology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0575","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12177","article-title":"Bleomycin-induced lung injury: Revisiting an old tool to model group III PH associated with pulmonary fibrosis","volume":"13","author":"Santos-Ribeiro","year":"2023","journal-title":"Pulmonary Circulation"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0580","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.biopha.2004.05.006","article-title":"Down-regulation of lipoxin A4 receptor by thromboxane A2 signaling in RAW246.7 cells in vitro and bleomycin-induced lung fibrosis in vivo","volume":"58","author":"Sato","year":"2004","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0585","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1165\/rcmb.2016-0147OC","article-title":"Lrp5\/beta-catenin signaling controls lung macrophage differentiation and inhibits resolution of fibrosis","volume":"56","author":"Sennello","year":"2017","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0590","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.smim.2015.03.004","article-title":"The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution","volume":"27","author":"Serhan","year":"2015","journal-title":"Seminars in Immunology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0595","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1084\/jem.192.8.1197","article-title":"Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing","volume":"192","author":"Serhan","year":"2000","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0600","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1096\/fj.11-201442","article-title":"Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain","volume":"26","author":"Serhan","year":"2012","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0605","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1073\/pnas.81.17.5335","article-title":"Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes","volume":"81","author":"Serhan","year":"1984","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0610","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1021\/jm201468j","article-title":"Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications","volume":"55","author":"Shen","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0615","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.intimp.2013.09.017","article-title":"Effects of montelukast on subepithelial\/peribronchial fibrosis in a murine model of ovalbumin induced chronic asthma","volume":"17","author":"Shin","year":"2013","journal-title":"International Immunopharmacology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0620","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1183\/09031936.00107206","article-title":"Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant","volume":"30","author":"Shorr","year":"2007","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0625","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1172\/JCI119590","article-title":"Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung","volume":"100","author":"Sime","year":"1997","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0630","doi-asserted-by":"crossref","first-page":"11657","DOI":"10.1038\/s41598-020-68336-0","article-title":"Therapeutic targeting of 15-PGDH in murine pulmonary fibrosis","volume":"10","author":"Smith","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0635","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0163-7827(03)00049-3","article-title":"Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function","volume":"43","author":"Spector","year":"2004","journal-title":"Progress in Lipid Research"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084063","article-title":"Endothelial dysfunction exacerbates renal interstitial fibrosis through enhancing fibroblast Smad3 linker phosphorylation in the mouse obstructed kidney","volume":"8","author":"Sun","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0645","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1074\/jbc.M609212200","article-title":"Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation","volume":"282","author":"Sun","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0650","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1084\/jem.20182351","article-title":"A homozygous SFTPA1 mutation drives necroptosis of type II alveolar epithelial cells in patients with idiopathic pulmonary fibrosis","volume":"216","author":"Takezaki","year":"2019","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0655","doi-asserted-by":"crossref","first-page":"2438247","DOI":"10.1155\/2017\/2438247","article-title":"Maresin 1 mitigates high glucose-induced mouse glomerular mesangial cell injury by inhibiting inflammation and fibrosis","volume":"2017","author":"Tang","year":"2017","journal-title":"Mediators of Inflammation"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0660","doi-asserted-by":"crossref","first-page":"7265486","DOI":"10.1155\/2022\/7265486","article-title":"Epoxyeicosatrienoic acids inhibit the activation of murine fibroblasts by blocking the TGF-beta1-Smad2\/3 signaling in a PPARgamma-dependent manner","volume":"2022","author":"Tao","year":"2022","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0665","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20212414","article-title":"EP3 enhances adhesion and cytotoxicity of NK cells toward hepatic stellate cells in a murine liver fibrosis model","volume":"219","author":"Tao","year":"2022","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0670","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01267-22","article-title":"Cysteinyl maresins reprogram macrophages to protect mice from streptococcus pneumoniae after influenza A virus infection","volume":"13","author":"Tavares","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0675","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.pharmthera.2019.02.001","article-title":"Quenching the fires: Pro-resolving mediators, air pollution, and smoking","volume":"197","author":"Thatcher","year":"2019","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0680","doi-asserted-by":"crossref","first-page":"L22","DOI":"10.1152\/ajplung.00428.2016","article-title":"Transforming growth factor-beta plays divergent roles in modulating vascular remodeling, inflammation, and pulmonary fibrosis in a murine model of scleroderma","volume":"312","author":"Tsujino","year":"2017","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0685","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s43440-021-00271-x","article-title":"Formyl peptide receptor 2, as an important target for ligands triggering the inflammatory response regulation: a link to brain pathology","volume":"73","author":"Tylek","year":"2021","journal-title":"Pharmacological Reports"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0690","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0033-2018","article-title":"Matrix abnormalities in pulmonary fibrosis","volume":"27","author":"Upagupta","year":"2018","journal-title":"European Respiratory Review"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0695","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1161\/CIRCRESAHA.116.309492","article-title":"Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice","volume":"119","author":"Viola","year":"2016","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0700","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs azathioprine in second-line therapy of sarcoidosis","volume":"144","author":"Vorselaars","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0705","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pharmthera.2017.06.006","article-title":"Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases","volume":"180","author":"Wagner","year":"2017","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0710","first-page":"5.46.1","article-title":"Mouse models of bleomycin-induced pulmonary fibrosis","author":"Walters","year":"2008","journal-title":"Current Protocols in Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106443","article-title":"Regulatory T cells are a double-edged sword in pulmonary fibrosis","volume":"84","author":"Wang","year":"2020","journal-title":"International Immunopharmacology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0720","first-page":"5592","article-title":"TGF-beta1\/Smad3 signaling promotes collagen synthesis in pulmonary artery smooth muscle by down-regulating miR-29b","volume":"11","author":"Wang","year":"2018","journal-title":"International Journal of Clinical and Experimental Pathology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0725","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/SHK.0000000000000446","article-title":"Maresin 1 inhibits epithelial-to-mesenchymal transition in vitro and attenuates bleomycin induced lung fibrosis in vivo","volume":"44","author":"Wang","year":"2015","journal-title":"Shock"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0730","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2613.2002.00229.x","article-title":"Titration of non-replicating adenovirus as a vector for transducing active TGF-beta1 gene expression causing inflammation and fibrogenesis in the lungs of C57BL\/6 mice","volume":"83","author":"Warshamana","year":"2002","journal-title":"International Journal of Experimental Pathology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0735","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","article-title":"Interstitial lung diseases","volume":"400","author":"Wijsenbeek","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0740","doi-asserted-by":"crossref","first-page":"L525","DOI":"10.1152\/ajplung.00163.2007","article-title":"TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease","volume":"293","author":"Willis","year":"2007","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0745","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0002-9440(10)62351-6","article-title":"Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis","volume":"166","author":"Willis","year":"2005","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0750","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1083\/jcb.200704042","article-title":"Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix","volume":"179","author":"Wipff","year":"2007","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0755","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1165\/rcmb.2005-0184OC","article-title":"Lipoxin A4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor","volume":"34","author":"Wu","year":"2006","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0760","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000315121","article-title":"Lipoxin A(4) inhibits transition of epithelial to mesenchymal cells in proximal tubules","volume":"32","author":"Wu","year":"2010","journal-title":"American Journal of Nephrology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0765","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/gerona\/glp040","article-title":"Use of senescence-accelerated mouse model in bleomycin-induced lung injury suggests that bone marrow-derived cells can alter the outcome of lung injury in aged mice","volume":"64","author":"Xu","year":"2009","journal-title":"The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0770","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1165\/rcmb.2020-0504OC","article-title":"Connective-tissue growth factor contributes to TGF-beta1-induced lung fibrosis","volume":"66","author":"Yanagihara","year":"2022","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0775","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1165\/rcmb.2013-0440OC","article-title":"Soluble epoxide hydrolase inhibitor attenuates inflammation and airway hyperresponsiveness in mice","volume":"52","author":"Yang","year":"2015","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0780","doi-asserted-by":"crossref","first-page":"L1013","DOI":"10.1152\/ajplung.00415.2018","article-title":"Resolvin D1 attenuates mechanical stretch-induced pulmonary fibrosis via epithelial-mesenchymal transition","volume":"316","author":"Yang","year":"2019","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0785","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/s41418-018-0175-7","article-title":"Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis","volume":"26","author":"Yao","year":"2019","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0790","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/mt.2016.36","article-title":"Chop deficiency protects mice against bleomycin-induced pulmonary fibrosis by attenuating M2 macrophage production","volume":"24","author":"Yao","year":"2016","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0795","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/intimm\/dxab026","article-title":"Genetics and animal models of familial pulmonary fibrosis","volume":"33","author":"Yasutomo","year":"2021","journal-title":"International Immunology"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0800","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.12628","article-title":"17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice","volume":"3","author":"Yatomi","year":"2015","journal-title":"Physiological Reports"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0810","doi-asserted-by":"crossref","first-page":"36059","DOI":"10.1074\/jbc.R100030200","article-title":"Epoxygenase pathways of arachidonic acid metabolism","volume":"276","author":"Zeldin","year":"2001","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0815","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1007\/s10620-021-07356-w","article-title":"Resolvin D1 prevents epithelial-to-mesenchymal transition and reduces collagen deposition by stimulating autophagy in intestinal fibrosis","volume":"67","author":"Zeng","year":"2022","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0820","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12931-018-0864-2","article-title":"Macrophages: friend or foe in idiopathic pulmonary fibrosis?","volume":"19","author":"Zhang","year":"2018","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0825","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1471-2466-14-64","article-title":"Pulmonary delivery of docosahexaenoic acid mitigates bleomycin-induced pulmonary fibrosis","volume":"14","author":"Zhao","year":"2014","journal-title":"BMC Pulmonary Medicine"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0830","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00079-2015","article-title":"Lipoxin A(4) promotes lung epithelial repair whilst inhibiting fibroblast proliferation","author":"Zheng","year":"2016","journal-title":"ERJ Open Research"},{"key":"10.1016\/j.pharmthera.2023.108460_bb0835","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/labinvest.2017.114","article-title":"ResolvinD(1) stimulates epithelial wound repair and inhibits TGF-beta-induced EMT whilst reducing fibroproliferation and collagen production","volume":"98","author":"Zheng","year":"2018","journal-title":"Laboratory Investigation"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108460_bb0805","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/JPER.22-0462","article-title":"Resolvin D1 modulates periodontal ligament fibroblast function","volume":"94","author":"Zarrough","year":"2023","journal-title":"Journal of Periodontology."}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823001249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823001249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:34:41Z","timestamp":1759012481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725823001249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":167,"alternative-id":["S0163725823001249"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108460","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is there a role for specialized pro-resolving mediators in pulmonary fibrosis?","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108460"}}